Annual Meeting 2016: Nivolumab and pembrolizumab and the current treatment landscape for Hodgkin lymphoma - 101793

Spotlight
Video

Annual Meeting 2016: Nivolumab and pembrolizumab and the current treatment landscape for Hodgkin lymphoma

VJHemOnc has 915 videos Subscribe Here

Loading........
Description: Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the place of nivolumab and pembrolizumab in the current treatment landscape for relapsed Hodgkin lymphoma. According to Prof Younes, the approval by the FDA is very specific and requires that patients have had a failed autologous stem cell transplant and brentuximab vedotin. He further discusses how the new combinations may change the treatment landscape.
Recorded at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, in Chicago, IL.
Shared By : VJHemOnc
Posted on : 06/17/16
Added : 2 years ago
Category : Hodgkin Lymphoma



Recommended

Nothing found.

More From VJHemOnc

Nothing found.